CDKN2A and alpha thalassemia spectrum: Although most models developed focus on IDH-mutation prediction, studies have also been directing their attention to other markers such as 1p/19q codeletion, homozygous deletion of the cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B), alpha-thalassemia/mental retardation X-linked (ATRX) mutation, EGFR amplification, TP53 mutation, capicua transcriptional repressor (CIC) mutation, etc., since last year with quite promising results [25,112].